Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

733 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Application of proteomics in ovarian cancer: which sample should be used?
Cadron I, Van Gorp T, Timmerman D, Amant F, Waelkens E, Vergote I. Cadron I, et al. Among authors: vergote i. Gynecol Oncol. 2009 Dec;115(3):497-503. doi: 10.1016/j.ygyno.2009.09.005. Epub 2009 Oct 6. Gynecol Oncol. 2009. PMID: 19811810 Review.
Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer.
Vergote I, Himmelmann A, Frankendal B, Scheistrøen M, Vlachos K, Tropé C. Vergote I, et al. Gynecol Oncol. 1992 Dec;47(3):282-6. doi: 10.1016/0090-8258(92)90127-5. Gynecol Oncol. 1992. PMID: 1473738
Distribution of intraperitoneally injected microspheres labeled with the alpha-emitter astatine (211At) compared with phosphorus (32P) and yttrium (90Y) colloids in mice.
Vergote I, Larsen RH, De Vos L, Winderen M, Ellingsen T, Bjørgum J, Hoff P, Aas M, Tropé C, Nustad K. Vergote I, et al. Gynecol Oncol. 1992 Dec;47(3):358-65. doi: 10.1016/0090-8258(92)90140-e. Gynecol Oncol. 1992. PMID: 1473750
Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model.
Vergote I, Larsen RH, de Vos L, Nesland JM, Bruland O, Bjørgum J, Alstad J, Tropé C, Nustad K. Vergote I, et al. Gynecol Oncol. 1992 Dec;47(3):366-72. doi: 10.1016/0090-8258(92)90141-5. Gynecol Oncol. 1992. PMID: 1473751
CA125 in peritoneal fluid of ovarian cancer patients.
Vergote IB, Onsrud M, Børmer OP, Sert BM, Moen M. Vergote IB, et al. Gynecol Oncol. 1992 Feb;44(2):161-5. doi: 10.1016/0090-8258(92)90032-e. Gynecol Oncol. 1992. PMID: 1544593
Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer.
Vergote IB, Vergote-De Vos LN, Abeler VM, Aas M, Lindegaard MW, Kjørstad KE, Tropé CG. Vergote IB, et al. Among authors: vergote de vos ln. Cancer. 1992 Feb 1;69(3):741-9. doi: 10.1002/1097-0142(19920201)69:3<741::aid-cncr2820690322>3.0.co;2-g. Cancer. 1992. PMID: 1730124 Clinical Trial.
The estimated 5-year crude survival rate was as high as 95% in patients with borderline or well-differentiated tumors in Stage I. ...Patients with moderately or poorly differentiated cancers in Stage I disease had a 5-year crude survival rate of 75%. In these patien …
The estimated 5-year crude survival rate was as high as 95% in patients with borderline or well-differentiated tumors in Stage I. ... …
Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors.
Tropé C, Kaern J, Vergote IB, Kristensen G, Abeler V. Tropé C, et al. Among authors: vergote ib. Gynecol Oncol. 1993 Nov;51(2):236-43. doi: 10.1006/gyno.1993.1279. Gynecol Oncol. 1993. PMID: 8276300 Review.
After surgery, 253 stage I-II borderline tumors without residual disease were randomly allocated to these protocols. The adjuvant treatment in the four trials consisted of [1] external irradiation (Ext) combined with intraperitoneal instillation of radioactive gold (198Au) …
After surgery, 253 stage I-II borderline tumors without residual disease were randomly allocated to these protocols. The adjuvant tre …
733 results
Jump to page
Feedback